Global initiative launches to speed up the discovery of new drugsBMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d1074 (Published 16 February 2011) Cite this as: BMJ 2011;342:d1074
- Anne Gulland
An Oxford University academic is spearheading a global initiative to speed up the development and discovery of new drugs.
Chas Bountra, chief scientist and head of the Structural Genomics Consortium at Oxford University, told a press briefing organised by the Science Media Centre that the global initiative, as yet unnamed, would be up and running by the end of this year to start research into diseases such as dementia, which are traditionally seen as too high risk by the drug industry.
Dr Bountra said the initiative would be a public-private partnership made up of academic institutions, drug firms, governments, regulators, and philanthropic organisations. “What we are proposing to set up is a global initiative—a public-private partnership—to work with completely novel drugs and take these to phase II [clinical trials] as quickly as we can. And we are going to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial